Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ANNX

Annexon, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ANNX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Annexon, Inc. (NASDAQ: ANNX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 15:01 UTC.

What Annexon, Inc. does

Annexon is a biopharmaceutical company developing targeted immunotherapies designed to block the classical complement pathway, which the company believes plays a role in neuroinflammatory diseases affecting millions of people globally. The company's approach focuses on stopping the pathway at its earliest stage by targeting C1q, aiming to provide protection against complement-mediated disorders in the brain, body, and eye.

Summarized from Annexon, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for ANNX are available in Oxford Ledge.
Open ANNX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-25
  • 2026-09-25PRESIDENT AND CEOPurchase26,065$99.8K
  • 2026-08-12DirectorStock Option (Right to Buy)Award175,000—
  • 2026-06-15EVP & CHIEF INNOVATION OFFICERStock Option (Right to Buy)Option exercise-30,646—
Sign in to see all transactions →

Company news

View all →
For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ANNX and 5,000+ tickers.

Create a free account — keep ANNX
For your agent
GET /api/data?ticker=ANNX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt